Company Overview: Prima Biomed Ltd

Industry News

10 Jul

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial

SYDNEY, Australia, July 09, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (PBMD) (“Prima” the “Company”) today announced that its collaboration partner, the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany (“IKF”), has received the regulatory and ethical approvals for the clinical trial investigating IMP321 in...

Read more

26 Jun

Operational Update

SYDNEY, Australia, June 26, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (PBMD), has provided an update on the Company’s two active clinical trials in IMP321. Prima is pleased to advise that clinical studies of IMP321 are progressing well. TACTI-mel (Two ACTive Immunotherapeutics in melanoma), the Company’s Australian melanoma trial,...

Read more

11 Jun

Prima BioMed Receives a Research Tax Credit Cash Rebate in France

Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, is pleased to announce that it has received EUR 226,055 (approximately A$320,000) in a cash rebate from the French state under the Crédit d’Impôt Recherche scheme. The cash rebate was paid in respect of...

Read more

4 Jun

Prima BioMed to Maintain NASDAQ Listing

Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) (“Prima”, the “Company”), announces that, further to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market, indicating that, for the 10 consecutive business days from...

Read more

11 May

Prima BioMed Announces Japanese Collaboration

Prima BioMed Ltd (ASX: PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) announces a collaboration with NEC Corporation and Yamaguchi University for Immutep’s IMP321 in combination with a peptide vaccine developed by NEC and Yamaguchi University. The preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate...

Read more

2 Mar

Prima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3

Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) Highlights Prima to focus on developing its highly prospective Immune checkpoint LAG-3 based immuno-oncology programs Recruitment for CAN-004B and CAN-301 clinical trials for CVac to cease Significant reduction in annual operational costs Pursuing opportunities to partner CVac and monetize its cancer vaccine infrastructure CAN 003 final overall survival...

Read more

28 Jan

Prima BioMed to Receive Financial Milestone Payment From GSK

Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima,” the “Company”) announces the first dosing of a subject by GSK in a Phase 1, first-in-human clinical trial of a novel depleting anti-LAG-3 antibody (GSK2831781)  for the treatment of autoimmune diseases. Prima’s CEO, Marc Voigt, said the beginning of the Phase 1...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address